Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of surufatinib combined with CAPTEM for advanced unresectable or metastatic neuroendocrine tumors
ChiCTR2300074945Phase 2Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Jan 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of surufatinib, capecitabine and temozolomide in apudoma (NET), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Progression-free survival. Started Jan 2022; status: recruiting.
02
Drugs
surufatinibcapecitabinetemozolomide
03
Conditions
apudoma (NET)
Beyond the preview
Go deeper on ChiCTR2300074945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300074945.